AbbVie Inc. (ABBV)
Health Care18 articles
Price chart
AbbVie Inc. (ABBV) overview
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
AbbVie Inc. trades on the NYSE under the ticker symbol ABBV. As of the most recent market data, the stock was priced around $256.42, up 0.37% on the session, giving AbbVie Inc. a market capitalization of roughly $453.12B.
Over the past 52 weeks, ABBV has traded between $190.75 and $267.47. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 72.0, a common gauge of how richly the market prices the company's earnings. AbbVie Inc. also pays a dividend, currently yielding around 2.71%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch ABBV
As one of the larger companies in the Health Care sector, AbbVie Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch ABBV for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, AbbVie Inc.'s size means its share-price moves can also nudge the index as a whole, making ABBV a stock that even index investors pay attention to.
Market Mood
Latest ABBV news
AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
In FY 2025, AbbVie Inc (NYSE:ABBV) reported revenue of nearly $61.2 billion, growing 8.7% from the previous year, with net income around $4.3 billion. Eli Lilly and Co (NYSE:LLY) achieved revenue of approximately $65.2 billion, a significant increase of 45% year-over-year, and net income around $20.6 billion. AbbVie's revenue is heavily reliant on Skyrizi and Rinvoq, while Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, significantly contribute to its growth. Investors should note the differing risk profiles, with AbbVie facing patent expiration pressures and price reductions affecting certain products, which may influence investment choices.
Read More: AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
Altria (MO), Chevron (CVX): 4% Yield Dividend Stocks Insight
Altria (MO) and Chevron (CVX) are part of a three-stock dividend strategy providing a 4% yield and monthly paychecks. Altria recently paid $1.06 per share, holding steady for three quarters, with a share price of $68.08 and a 6.19% dividend yield. AbbVie (ABBV) also contributes, having paid $1.73 per share recently, with its share price at $259.76 and a 2.58% yield. This strategy helps investors receive dividends throughout the year, making it relevant for those seeking consistent income from their investments.
Read More: Altria (MO), Chevron (CVX): 4% Yield Dividend Stocks Insight
AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
AbbVie (ABBV) presented lung cancer data at the World Conference on Lung Cancer (WCLC) 2026, including results for ABBV-1480, which achieved a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy. Safety data for ABBV-706 showed nausea in 35.8% of patients and grade 3+ pneumonitis or interstitial lung disease in 1.7% of patients.
Read More: AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
AbbVie (ABBV) management projects $12.7 billion in sales from its neuroscience division this year. The company is focusing on expanding its portfolio in this area, which is becoming an increasingly significant part of its operations. This projection reflects AbbVie's strategy to leverage its existing resources and expertise to capitalize on growth in the neuroscience market. For investors, the anticipated earnings could signal positive momentum for AbbVie's stock performance as it strengthens its market position.
Read More: AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
AbbVie (ABBV) Stock Declines Amid Market Uncertainty
AbbVie (ABBV) shares are experiencing a decline today due to market uncertainties affecting investor sentiment. Specific figures regarding the percentage decline or trading volume have not been mentioned, but heightened volatility can often lead to shifts in stock performance. Analysts have noted that fluctuations in broader market trends could be contributing factors to AbbVie's current stock situation. For investors, understanding these market trends is crucial in making informed decisions about holding or trading AbbVie shares.
Read More: AbbVie (ABBV) Stock Declines Amid Market Uncertainty
AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
AbbVie (ABBV) adjusted its 2026 profit forecast downwards due to the acquisition of Apogee Therapeutics. The company reported second-quarter earnings that exceeded analyst expectations. The updated guidance reflects the financial implications of the acquisition, affecting projected profitability. This revision is significant for investors as it impacts future earnings expectations and may influence AbbVie's stock performance.
Read More: AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
JPMorgan has identified Eli Lilly, AbbVie, and Danaher Corporation as top picks within the healthcare sector. Investors are currently overlooking these stocks, which may present buying opportunities. The recommendation suggests potential growth in these companies as market dynamics shift. This could lead to increased interest and investment in these healthcare stocks, impacting their market performance positively for investors. Eli Lilly (LLY), AbbVie (ABBV), and Danaher (DHR) are highlighted for consideration.
Read More: JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
AbbVie (ABBV) Stock May Move 4.2% on July 31 Earnings Report
AbbVie (ABBV) is expected to see a stock price movement of 4.2% following its earnings report scheduled for July 31. This level of volatility suggests that investors are anticipating significant financial metrics from the company. The upcoming earnings could impact investor sentiment and stock performance as market participants digest AbbVie's financial results. This matters for ordinary investors as it indicates possible short-term price fluctuations based on the company's reported performance.
Read More: AbbVie (ABBV) Stock May Move 4.2% on July 31 Earnings Report
AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
AbbVie (ABBV) announced a quarterly dividend of $1.73 with a yield of 2.8%, extending its streak of increases since 2013. In contrast, Baxter (BAX) eliminated its dividend, reporting a net income loss of $900 million for FY2025, which disqualifies it from income-focused portfolios. AbbVie's revenue growth from Skyrizi and Rinvoq, at 31% and 23%, respectively, has helped offset losses from Humira and raised guidance for the year. The contrast between the two companies highlights the risks and potential for investors focused on income reliability and growth.
Read More: AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
Jefferies has recommended quality, low-stress stocks amid increasing market volatility related to artificial intelligence investments. They specifically highlight AbbVie (ABBV), predicting nearly 28% compound annual earnings growth for 2026-2027 and a free cash flow yield of 5.2%. AbbVie's first-quarter net revenues reached $15 billion, led by its immunology portfolio of $7.3 billion. The stock has appreciated 25% over the last three months and 37% in the past year, offering a yield of 2.7%. This is important for investors as it suggests stable investment options amidst market fluctuations.
Read More: Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
AbbVie (ABBV) reached a new 52-week high, marking a 40% increase over the past year. Year-to-date, the stock has risen approximately 11%, outperforming the S&P 500's 8% gain. AbbVie trades at less than 18 times its estimated future earnings, below the S&P 500 average of 21. The company recently announced a $10.9 billion acquisition of Apogee Therapeutics, which will enhance its immunology portfolio, suggesting long-term growth potential amidst a strong earnings performance.
Read More: AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
AbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion. The focus of this acquisition is Apogee's development of an experimental drug for atopic dermatitis, a type of eczema. This move is significant for AbbVie as it expands its portfolio in dermatological treatments. The transaction underscores the ongoing trend of consolidations in the biotech sector to enhance product pipelines.
Read More: AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
AbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion, marking its largest buyout in over five years. The $135.11 per share offer represents a 49.49% premium to Apogee's prior closing price, prompting Apogee's shares to surge 48% to $133.77 in premarket trading. The acquisition aims to enhance AbbVie's next-generation immunology pipeline, particularly through the lead drug candidate, zumilokibart. The deal is expected to close in Q3 and contribute positively to AbbVie's adjusted earnings per share by 2032, as pharmaceutical dealmaking accelerates amid patent expirations.
Read More: AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
A $1 million dividend portfolio generates approximately $43,770 annually, subjected to $7,515 in taxes at the 24% bracket. This portfolio includes holdings such as Realty Income (O), Schwab U.S. Dividend Equity ETF (SCHD), and Johnson & Johnson (JNJ). The taxable portion of income is divided into qualified and ordinary income, impacting the total tax liability. The advantage of using a Roth IRA allows the full income to remain untaxed, highlighting the significance of account placement for tax efficiency.
Read More: Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, representing a 9.9% year-over-year increase, driven by TREMFYA's growth of 68.3% and DARZALEX's increase of 22.5% to $3.96 billion. The company raised its full-year guidance to a midpoint of $100.8 billion. AbbVie (ABBV) also exceeded expectations with Q1 revenue of $15 billion and a year-over-year increase of 12.4%. AbbVie's Skyrizi reached $4.48 billion with a 30.9% increase, offsetting Humira's 38.6% decline.
Read More: Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales
AbbVie (ABBV) reported quarterly earnings that exceeded analysts' expectations, driven by sales from newer immunology drugs that compensated for the decline in Humira's revenue. The company showcased a positive trend as net revenue from immunology reached $2 billion, while Humira sales decreased by 33% to $1.5 billion. This change reflects the ongoing transition to newer therapies, which may bolster AbbVie's market position. The performance indicates potential for recovery and growth, impacting investor sentiment positively.
Read More: AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales
AbbVie (ABBV) Tops Quarterly Estimates with $15 Billion Revenue
AbbVie (ABBV) reported quarterly revenue of $15 billion, exceeding analyst expectations of $14.72 billion. Profit per share was $2.65, surpassing forecasts of $2.59. Skyrizi sales reached $4.48 billion, growing 30.9%, while Rinvoq saw a 23.3% increase to $2.12 billion. In contrast, Humira's sales decreased by 38.6% to $688 million, missing estimates of $696.5 million. AbbVie also raised its adjusted earnings forecast for the year to $14.08 to $14.28 per share from the previous range of $13.96 to $14.16.
Read More: AbbVie (ABBV) Tops Quarterly Estimates with $15 Billion Revenue
AbbVie (ABBV) Ovarian Cancer Drug Shows 62.7% Response Rate
AbbVie's (ABBV) ovarian cancer drug demonstrated a response rate of 62.7% in clinical trials. This figure is significant as it reflects the drug's potential efficacy and could influence treatment options for patients. The results may impact AbbVie's stock performance in the biopharmaceutical market, considering the ongoing demand for effective oncology therapies. If approved, this drug could enhance AbbVie's position in the oncology segment.
Read More: AbbVie (ABBV) Ovarian Cancer Drug Shows 62.7% Response RateMore Health Care stocks
Frequently asked questions
Is AbbVie Inc. in the S&P 500?
Yes. AbbVie Inc. (ABBV) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is ABBV in?
AbbVie Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest ABBV news?
This page collects recent AbbVie Inc. (ABBV) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is AbbVie Inc.'s stock price?
As of the most recent market data, AbbVie Inc. (ABBV) traded at approximately $256.42. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is AbbVie Inc.'s market cap?
AbbVie Inc. has a market capitalization of roughly $453.12B, based on its most recent share price and shares outstanding.
What is ABBV's P/E ratio?
ABBV trades at a trailing price-to-earnings ratio of about 72.0. The P/E ratio compares a company's share price to its earnings per share.